TP53 mutation promotes sunitinib resistance in gallbladder cancer via the ARHGEF7-AS2/miR-326/AXL pathway.
Journal: Acta pharmaceutica Sinica. B
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Yang L, Zhan M, Yang R, et al. (2026). "TP53 mutation promotes sunitinib resistance in gallbladder cancer via the ARHGEF7-AS2/miR-326/AXL pathway.". Acta pharmaceutica Sinica. B. https://doi.org/10.1016/j.apsb.2026.08.019